HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ 5 G / 100 ML — DIN 02209721
DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 10000 UNIT / 100 ML · B. BRAUN MEDICAL INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ?
HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ 5 G / 100 ML contains DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 10000 UNIT / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02209721, held by B. BRAUN MEDICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 17-Jun-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ used for?
Anticoagulant therapy; prophylaxis/treatment of venous thrombosis, pulmonary embolism, peripheral arterial embolism; atrial fibrillation with embolization; DIC; prevention of clotting in surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Heparin, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Heparin, Combinations, across 8 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| B. BRAUN MEDICAL INC | 4 | 3 | HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ, HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ, HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION, HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML | Sourceable in Canada |
| BAXTER CORPORATION | 4 | 1 | HEPARIN SOD AND 0.9% SOD CHLORIDE INJ, HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ, HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ, HEPARIN SODIUM AND DEXTROSE 5% INJ USP | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 G / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Supplied in plastic containers (Excel Container). Specific sizes mentioned in summary table include 4,000, 5,000, and 10,000 units. |
| Storage | Store at room temperature (25°C); brief exposure up to 40°C permitted. Avoid excessive heat. Protect from freezing. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Heparin, Combinations |
|---|---|
| ATC code | B01AB51 |
| AHFS class | 20:12.04.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02209721 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2209721 |
| Brand name | HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ |
| Generic / active ingredient | DEXTROSE : 5 G / 100 ML HEPARIN SODIUM : 10000 UNIT / 100 ML |
| Market authorization holder | B. BRAUN MEDICAL INC |
| Health Canada schedule | Ethical |
| ATC code | B01AB51 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AB |
| Current status | MARKETED |
| Status date | 17-Jun-1998 |
| Original market date | 1996-09-10 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Continuous IV infusion. Initial dose: 5,000 units. Maintenance: 20,000 - 40,000 units/24 hours. Adjust dose based on APTT (1.5-2x normal) or clotting time (2.5-3x control).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Severe thrombocytopenia; inability to perform coagulation tests; uncontrollable active bleeding; hypersensitivity to heparin, corn products, or any ingredient.
Warnings and precautions
Serious Warning: Fatal hemorrhages in pediatrics due to medication errors. Risk of hemorrhage at any site. Heparin-induced Thrombocytopenia (HIT/HITT). Contains sodium metabisulfite.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPARIN SOD AND 0.9% SOD CHLORIDE INJ | 2 UNIT | SOLUTION | BAXTER CORPORATION | MARKETED | 00828750 |
| HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ | 4000 UNIT / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 02209713 |
| HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 01935941 |
| HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 02008181 |
| HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 01900757 |
| HEPARIN SODIUM AND DEXTROSE 5% INJ USP | 5 G / 100 ML | LIQUID | BAXTER CORPORATION | CANCELLED POST MARKET | 01913255 |
| HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION | 430 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | DORMANT | 01935933 |
2 · Same class — other molecules in ATC B01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Enoxaparin | AXBERI · AXBERI HP · ELONOX · ELONOX HP · +9 more | 46 | 44 | Yes |
| Tinzaparin | INNOHEP · INNOHEP DISP.SYR.-11700 ANTI-XA IU/ML · LOGIPARIN LIQ SC 10000 FXAIU/ML | 13 | 11 | Yes |
| Heparin | CALCILEAN INJ 20000UNIT/0.8ML · CALCIPARINE INJ 20000IU/AMP · CALCIPARINE INJ 5000IU · HEPALEAN 10,000 USP · +17 more | 32 | 10 | Yes |
| Dalteparin | FRAGMIN · FRAGMIN INJ.-LIQ 2500 IU(ANTI-XA)/ML | 13 | 10 | Yes |
| Heparin, Combinations | HEPARIN SOD AND 0.9% SOD CHLORIDE INJ · HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ · HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ · HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ · +4 more | 8 | 4 | Yes |
| Antithrombin | ANTITHROMBIN III IMMUNO · ANTITHROMBIN III NF · THROMBATE III · THROMBATE III PWS IV 1000IU/VIAL · +1 more | 7 | 2 | Yes |
| Danaparoid | ORGARAN | 1 | 1 | Yes |
| Nadroparin | FRAXIPARINE · FRAXIPARINE FORTE | 8 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · +10 more | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.